ERDAFITINIB (erdafitinib) by Johnson & Johnson is fgfr1, fgfr2, fgfr3 and fgfr4 based on in vitro data. Approved for metastatic urothelial carcinoma (muc) with susceptible fgfr3 genetic alterations whose disease has progressed on, after at least one line of prior systemic therapy.
Drug data last refreshed 1mo ago
FGFR1, FGFR2, FGFR3 and FGFR4 based on in vitro data. Erdafitinib inhibited FGFR phosphorylation and signaling and decreased cell viability in cell lines expressing FGFR genetic alterations, including point mutations, amplifications, and fusions. Erdafitinib demonstrated antitumor activity in…
Worked on ERDAFITINIB at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants